Radiation-induced maculopathy may respond better to dexamethasone

COLORADO SPRINGS, Colo. — Recalcitrant radiation maculopathy after iodine-125 brachytherapy for uveal melanoma responded better to intravitreal dexamethasone rather than bevacizumab or triamcinolone, according to a scientific poster presented at the American Ophthalmological Society meeting here.“Radiation maculopathy develops quite frequently following I-125 brachytherapy of uveal melanoma. Initial treatment with bevacizumab and/or triamcinolone is variably effective,” William F. Mieler, MD, FARVO, wrote in the poster. “Recalcitrant [cystoid macular edema] appears to respond quite readily to intravitreal dexamethasone and perhaps should be considered earlier in the treatment regimen of radiation-induced maculopathy.”